A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

NCT04580121 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: RO7283420
DRUG: RO7283420
DRUG: Tocilizumab
DRUG: Dasatinib
DRUG: Dexamethasone
DRUG: Paracetamol/acetaminophen
DRUG: Diphenhydramine

Sponsor

Hoffmann-La Roche